RECENT NEWS
Diagnostics partnership for BD and Quest
BD (Becton Dickinson) and Quest Diagnostics have announced a global collaboration agreement to develop, manufacture and commercialise flow cytometry-based companion diagnostics (CDx) intended to help select the best treatment for patients with cancer and other diseases.
Proscia introduces major update to Concentriq AP
Proscia has introduced the next version of its enterprise pathology platform Concentriq AP. The release includes new functionality that advances the impact of AI in shaping pathologists’ understanding of four of the top five most common cancers worldwide.
IBMS backs UK COVID-19 Inquiry’s findings
The Institute of Biomedical Science (IBMS) has backed the conclusions and recommendations from the UK COVID-19 Inquiry’s first report, which include comprehensive and multidisciplinary planning, the involvement of a broader range of experts and a new independent statutory body responsible for whole system preparedness and response,
ProLab Diagnostics to host AMR action plan webinar
The next Pro-Lab Diagnostics scientific webinar will be ‘The second 5-year national antimicrobial resistance action plan: what's new’. An update on the UK’s 20-year vision for confronting antimicrobial resistance, it takes place on Tuesday 30 July, 12 noon – 1.00 pm.
UK hospitals trialling Paige’s AI to diagnose prostate cancer
In a collaborative project led by the University of Oxford, diagnostic artificial intelligence (AI) applications from Paige are being trialled as part of a live, multisite clinical use study to evaluate AI in the diagnosis of prostate cancer within the NHS.
COVID-19 Inquiry publishes first report and recommendations focused on preparedness
The Chair of the UK Covid-19 Inquiry, Baroness Heather Hallett, is urging the new UK government and the governments of Wales, Scotland and Northern Ireland to implement promptly her 10 key recommendations following publication of the Inquiry’s report of its first investigation into the nation’s resilience and preparedness for the pandemic.
National RSV vaccination programme announced
The UK will become the first country in the world to have a national programme that uses the same vaccine to protect newborns and also older adults against respiratory syncytial virus (RSV).
Beckman Coulter Diagnostics investing €10 million in County Clare, Ireland
Beckman Coulter Diagnostics has announced a €10 million investment for its manufacturing and research base in County Clare, Ireland, that underscores its commitment to innovation and growth in the region.
SARS-CoV-2 infections have a long-term impact on the immune system
In a study recently published in the renowned journal Allergy, a MedUni Vienna research team shows that COVID-19 leads to considerable long-term changes in the immune system, even in mild cases. The findings could help to better understand the long-term consequences of an infection with SARS-CoV-2.
MRC awards 2023 Impact Prize and Millennium Medal
Pioneering scientists were awarded the MRC Impact Prize to celebrate their achievements alongside those of the 2023 MRC Millennium Medal recipient.
Latest Beacon research collaboration to build next generation of smart microscopes
Danaher Corporation has launched a research collaboration with Stanford University's Department of Bioengineering intended to shape the future of cancer drug screening through ‘smart microscopy’. Combining spatial biology with artificial intelligence (AI), the research team at the Danaher Beacon for Spatialomics aims to help de-risk cancer drug development.
ALZpath and Beckman Coulter Diagnostics collaborating for Alzheimer’s diagnostic
ALZpath has signed a licensing agreement with Beckman Coulter Diagnostics for use of its best-in-class ALZpath pTau217 antibody in a blood-based in vitro diagnostic (IVD) test on the DxI 9000 Immunoassay Analyzer to advance Alzheimer's disease diagnosis.
Open-source AI foundation model for pathology launched
French startup Bioptimus has announced the release of H-optimus-0, which the company says is the world’s largest open-source AI foundation model for pathology. With 1.1 billion parameters, H-optimus-0 is trained on a proprietary dataset of several hundreds of millions of images extracted from over 500,000 histopathology slides across 4,000 clinical practices.
Philips IntelliSite Pathology Solution receives 510(k) clearance
Philips IntelliSite Pathology Solution 5.1 has received 510(k) clearance from the US Food and Drug Administration. Philips was first to market an FDA-approved digital pathology solution in 2017 and is the most widely deployed digital pathology solution for primary diagnosis around the world.
Thermo Fisher Scientific aiding myeloid cancer research with genomic sequencing
To help accelerate research into new treatments for acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), Thermo Fisher Scientific is partnering with the National Cancer Institute (NCI) – part of the US National Institutes of Health – on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial.
UK and US join forces to tackle dementia with innovative biomarkers
Innovate UK has awarded four UK companies a share of £4 million funding through Contracts for Innovation to support innovative research into dementia diagnosis.
Independent investigation ordered into state of NHS
Health and Social Care Secretary Wes Streeting has ordered a full and independent investigation into the state of the NHS, to uncover the extent of the issues facing the nation’s health service. Mr Streeting says he wants a ‘raw and honest’ assessment that will deliver ‘the hard truths’.
Gerry McKenna Award for Excellence in Medical Science
The Western Health and Social Care Trust in Northern Ireland has established the Annual Professor Gerry McKenna Award for staff excellence in medical science.
UK NEQAS hosting quality standards in POCT event
‘Navigating Quality Standards in Point of Care Testing’ is a day-long seminar hosted by UK NEQAS, taking place in Birmingham on 23 October, 2024.
Could RNAs assist in treatment decisions for stage II colon cancer patients?
RNAs may help identify stage II colon cancer patients who could benefit from chemotherapy following surgery. In a newly published study, investigators assess the biomarker potential of RNAs to identify such patients.
Latest Issues
Launch Diagnostics is one of the major independent distributors in the U.K, providing high quality diagnostic reagents and instrumentation from world leading manufacturer’s to the Health Services of the United Kingdom, France, Belgium, Netherlands, Luxemburg and North Africa and to the Republic of Ireland through ACCUSAY Diagnostics.
BSMT 40th Anniversary Microbiology Conference
RAF Museum, Hendon, London NW9 5LL
15 May, 2025
Transforming Digital Pathology & AI: The Path Forward
Royal College Of Physicians Of Edinburgh
15 May, 2025
The 10 Year Plan - Clinical Innovations Expo
Jubilee Hotel and Conference Centre, Nottingham, UK
15 May, 2025
Incorrect Blood Component Transfused: a SHOT webinar
Online
21 May 2025
Near miss reporting and WBIT: a SHOT webinar
Online
9 June 2025